Objective: Hydrocortisone via nasogastric (NG) tube is used in sick children with adrenal insufficiency; however, there is no licensed formulation for NG administration.
with hydrocortisone to reduce bronchopulmonary dysplasia in premature infants is becoming more popular 4 ; however, there are no licensed formulations for administration via NG tube.
Hydrocortisone is poorly soluble in aqueous solutions and the suspension is viscous and therefore its delivery may be adversely affected when intervening equipment such as syringes and NG tubes are used. 5 Inaccuracy in the hydrocortisone dose delivered leads to underor over-replacement and is associated with poor disease control and potentially poor long-term health outcomes. [6] [7] [8] For hydrocortisone administration via the NG route, the preparations most commonly used in paediatric practice are liquid suspensions (syrup) available as special unlicensed formulations and tablets crushed into a fine powder and mixed with water. [9] [10] [11] [12] A multi-particulate immediate-release formulation of hydrocortisone has been specifically developed for oral administration to neonates, infants and young children. 13, 14 This study investigated the in vitro recovery of hydrocortisone after pas- 
| ME THODS

| Protocol development and hydrocortisone formulations tested
The experimental protocol was developed following consultation with adult and paediatric endocrine specialist nurses, senior neonatal intensive care nurses, paediatric pharmacists and a review of current clinical practice. 9, [15] [16] [17] [18] In children, oral hydrocortisone is usually given in 3-4 daily doses from 0.5 mg upwards with the commonest dose being 2 mg, 2,3,13,19 so we chose to test doses of 0.5 and 2.0 mg (=target doses). Current practice in our institution is to use either liquid in suspension (100 mL bottle at 5 mg/5 mL) or crushed 10 mg hydrocortisone tablets. When using NG tubes in neonates, the total drug administration volumes should be minimal with NG flushes up to 2 mL, 15,17 so we chose to give doses in maximum 2 mL volume with 2 mL flush in the NG tubes 6-8Fr that are used in this age group. The protocol was tested on the bench multiple times, timed and supervised by a paediatric endocrine nurse to ensure compliance with clinical practice. Two researchers performed the experiments and all stages were timed for standardization.
| Protocol for preparation of hydrocortisone formulations for administration
• Liquid hydrocortisone suspension: the bottle (100 mL bottle at 5 mg/5 mL) was shaken vigorously and the required amount drawn into a sterile 10 mL syringe.
• Hydrocortisone tablets: one 10 mg tablet was crushed using a tablet crusher into a fine powder, 10 mL of sterile water were added and mixed and the required amount drawn into a sterile 10 mL syringe.
• Hydrocortisone granules: the contents of one capsule (0.5 mg or 2 mg) were suspended in 2 mL sterile water in a 10 mL sterile syringe, the suspension was shaken vigorously for 30 seconds, left on the bench for 15 minutes and then shaken again for 30 seconds.
| Hydrocortisone recovery at the nasal end of the NG tube
The experiment assessed the recovery of hydrocortisone in samples prepared for NG administration (but not administered) according to the above protocol. There were two parts in this experiment. In the first part two target doses, 0.5 and 2 mg were prepared as above and then expelled into bijou tubes. Six repeats were performed. The second part assessed whether the suboptimal recovery of hydrocortisone was due to dose remnants in the administering syringe: a second set of samples for the liquid suspension formulation was collected that included flushing of the administering syringe with 2 mL water. The flushing liquid was collected together with the sample for hydrocortisone quantification and three repeats were performed. The samples were stored at 4°C prior to analysis.
| Hydrocortisone administration through NG tubes
Nasogastric tubes come in variable sizes and are measured using the 
| Quantification of hydrocortisone by liquid chromatography tandem mass spectrometry
All samples were labelled with a numerical code, stored at 40 μL of 0.1 mol/L zinc sulphate was added. This was vortexed for 10 seconds followed by the addition of 100 μL of internal standard.
The block was heat-sealed (Thermo) and vortexed for 1 minutes, then centrifuged at 8000 g for 5 minutes. Following centrifugation, the plate was transferred directly to the autosampler for analysis; 10 μL of sample was injected into the liquid chromatography (LC) system using partial loop mode. LC-MS/MS was performed using an Acquity I Class coupled to a XEVO TQ-D detector (Waters, Wilmslow, UK). The quantity of hydrocortisone in mg in each sample was calculated from the hydrocortisone concentration. The inter-assay imprecision (%CV) was 13%, 9% and 5% at concentrations of 100, 400 and 800 nmol/L, respectively. The intra-assay imprecision was 12%, 7% and 9%.
| Data presentation and statistical analysis
Results are shown as mean ± SD of the repeats. The data are expressed either as mean hydrocortisone content in mg or % hydrocortisone recovery, that is, the mean hydrocortisone content in each set expressed as a percentage of the dose administered (target dose). ANOVA with multiple comparisons was used for the analysis of differences between the three hydrocortisone formulations and between the bench time rest periods allowed for the alternative preparation method for hydrocortisone granules suspension (GraphPad 7, GraphPad Software, La Jolla CA).
Unpaired two-tailed t tests were performed for comparison of pre-and post-NG administration recovery for each time point in the alternative method of preparation. A P value of <0.05 was considered significant. 
| RE SULTS
| Recovery of hydrocortisone prior to NG administration
The recovery of hydrocortisone from all three preparations at the nasal end of the NG tube prior to NG administration was low:
mean ± SD % recovery of target dose for doses 0.5 and 2.0 mg was; liquid suspension 57% ± 7% & 58% ± 18%, crushed hydrocortisone mixed with water 46% ± 18% & 30% ± 5%, hydrocortisone granules 78% ± 15% & 71% ± 4% (Figure 1 ). The delivery of hydrocortisone with hydrocortisone granules was significantly better than crushed hydrocortisone for the 0.5 mg dose (P < 0.01) and the 2 mg dose (P < 0.01), and the liquid suspension was better than the crushed hydrocortisone for the 2 mg dose (P < 0.01) (Figure 1 ).
The delivery of hydrocortisone in the pre-administration samples of the liquid suspension increased significantly following flushing of the administrating syringe; mean ± SD % recovery of target dose; 0.5 mg dose without flushing 57% ± 7% vs with flushing 147% ± 31% (P < 0.01); 2 mg dose without flushing 58% ± 18% vs with flushing 105% ± 8% (P < 0.01, Figure 2 ). Based on these results syringes for all formulations were flushed for the experiments using the NG tubes.
| Hydrocortisone recovery after passage through NG tubes
In this in vitro setting, it was possible to administer hydrocortisone through neonatal, paediatric and adolescent size NG tubes using all three preparations, although the delivery was variable. The hydrocortisone granules and the liquid suspension showed similar results throughout the range of NG tube sizes whereas the crushed hydrocortisone tablets gave greater variability for both doses ( Figure 3 , Table 1 ). The delivery of hydrocortisone for the 0.5 mg dose mean ± SD % recovery of target dose for the four different size NG tubes was; liquid suspension 65% ± 32% to 92% ± 34%, crushed hydrocortisone 59% ± 22% to 174% ± 118%, hydrocortisone granules 66% ± 13% to 83% ± 17% and for the 2 mg dose; liquid suspension 61% ± 14% to 65% ± 6%, crushed hydrocortisone 40% ± 5% to 96% ± 34%, hydrocortisone granules 61% ± 7% to 92% ± 14%.
The possibility of mechanical tube occlusion due to administration of hydrocortisone granules was further explored. Following nasogastric administration of hydrocortisone granules, the NG tubes were observed for granules; no remaining granules were visible in the 10 and 12Fr. However, hydrocortisone granules were trapped within 6 and 8Fr tubes and the water flush did not remove them completely (Figure 4 ).
Flushing the NG tubes immediately after administration of hydrocortisone granules was difficult although there was no complete occlusion of the NG tube during the administration phase. When NG tubes were left to drain for 30 minutes and a second flush was attempted complete occlusion was observed in 10% of 6Fr NG tubes and 50% of 8Fr NG tubes. Fewer granules were observed to enter the 6Fr NG tube compared to 8Fr tube.
| Recovery of hydrocortisone from hydrocortisone granules using an alternative method of preparation
To avoid granules entering the NG tube from the administering syringe, an alternative preparation method was developed and tested 
TA B L E 1 The recovery of hydrocortisone from three different hydrocortisone formulations administered through NG tubes, collected with water flush and quantified by LC-MS
| D ISCUSS I ON
We have shown that it is possible to administer hydrocortisone via a nasogastric tube; however, dose recovery at the gastric end of the nasogastric tube is very variable and generally less than that Hydrocortisone granules blocked the smaller NG tubes but this was avoided by generating a hydrocortisone suspension from the granules by leaving in water for 15 minutes and then using a sampling needle for drug aspiration that did not allow granules to be aspirated into the syringe.
Crushing oral medication to a fine powder is common practice for nasogastric administration in adults and children but it is an unlicensed use of the medication. 21 Compounding from adult dose formulations is common in paediatrics when no dose appropriate formulation is available, 13, 22 it is undertaken by pharmacy as well as carers and can lead to therapeutic failure among other risks. 23 Capsules prepared by pharmacy from compounded hydrocortisone tablets have been found to have unacceptably variable drug content in over 20% of batches and have led to clinically and biochemically evident glucocorticoid overtreatment. 7, 22 In our study, crushed hydrocortisone tablets mixed with water showed significant variability in the recovery of the administered hydrocortisone dose, usually with significantly low recovery but occasionally the recovery was above 100% of the target dose meaning that higher amount of hydrocortisone than the target dose (0.5 mg or 2 mg) was recovered in the sample.
This likely reflects problems with the current practice of preparing small doses from 10 mg adult dose tablets. Another factor could be the loss of active pharmaceutical ingredient that could be up to 10% of the mass during hydrocortisone compounding because hydrocortisone sticks in the equipment used for compounding. 24 Furthermore, hydrocortisone is relatively insoluble in water, 5, 25 which means most hydrocortisone is in suspension not solution.
Few studies have reported the administration of medications through NG tubes and none have reported on hydrocortisone.
26-29
Our results show suboptimal recovery of hydrocortisone at the gas- It is important to follow appropriate techniques when administering medications down NG tubes and this applies to patients and carers who can be trained to give medications through NG tubes in the community. However, medicines are usually used out of license and there is lack of data on the accuracy of drug delivery through this method. 9, 16, 30 We found that flushing the equipment (syringes) improves delivery for liquid suspension hydrocortisone.
This has implications in children treated with hydrocortisone via the oral route when intervening equipment such as syringes are used; flushing of devices is important to maximize recovery for hydrocortisone, which is poorly soluble in water and sticks to plastics. 5, 24 Our in vitro results demonstrate that specific methods need to be followed for different formulations of hydrocortisone to maximize recovery and accurate dosing and that most methods lead to under dosing. In conclusion, although delivery of hydrocortisone through NG tubes is possible, significant attention should be placed on the technique used to optimize drug delivery. The delivery of hydrocortisone with hydrocortisone granules was comparable with the currently used formulations and in fact granules seem to behave as well as the liquid suspension which is the current standard and most optimal formulation for oral administration; however, it leads to tube occlusions in the smaller gauge NG tubes (6 and 8Fr). Using a sampling needle to prevent the administration of granules is an alternative technique that delivers 74%-98% of the required target dose.
ACK N OWLED G EM ENTS
The authors would like to thank the Endocrine specialist nurses Victoria Ibbotson, Kay Dunkley, and Sally Carney, and the senior nursing staff on Neonatal Intensive Unit, Jessops Wing, Sheffield
Teaching Hospitals NHS Trust for sharing their clinical experience to inform protocol development. 
CO N FLI C T O F I NTE R E S T
